Secondary objectives :~Comparison of HIV-1 RNA level in plasma (threshold 20 and 1 copies/ml) and in seminal plasma (threshold 60 copies/ml) at each visit D0, W2, W4, W8, W12, W24, W36, W48~To assess the frequency of intermittent shedding in seminal plasma once virological suppression has been achieved and until W48~Evolution of cellular HIV-1 DNA level in PBMC and in non-sperm cells between D0 and W48~Comparison of dolutegravir concentration in blood plasma and seminal plasma~Study of risk factors associated with viral persistence of HIV-RNA in the seminal plasma~Analysis by deep sequencing of the viral population (quasi-species) in both compartments (blood plasma and seminal plasma) before virological suppression has been achieved (i.e. at D0 and W12)~Inclusion criteria :~Patients diagnosed at the time of primary HIV infection (PHI) (i) a negative or indeterminate HIV ELISA associated with a positive antigenemia or plasma HIV RNA, (ii) a western blot profile compatible with ongoing seroconversion (incomplete western blot with absence of antibodies to pol proteins (p34, p68)) or (iii) an initially negative test for HIV antibodies followed within 3 months by a positive HIV serology~Treatment including dolutegravir (DTG 50mg) + tenofovir/emtricitabine (TDF/FTC 245 mg/200 mg) initiated by the referee physician within a maximum of 15 days after diagnosis of PHI~Genotypic sensitivity to TDF, FTC and DTG~Patient with medical care insurance~Exclusion criteria :~Chronic infection~Infection or co-infection with HIV-2~Study treatment : Dolutegravir and tenofovir/emtricitabine Number of subjets : 20 patients (exploratory study)
Sponsor: IMEA - Fondation Internationale Léon Mba C.H.U. Bichat - Claude Bernard 46, Rue Henri Huchard - 75018 PARIS Tél. : 01.40. 25. 63. 65 - Fax : 01.40.25.63.56~Coordinating investigator:~Dr Caroline Lascoux Combe Hôpital Saint Louis Service Maladies Infectieuses~1 avenue Claude Vellefaux - 75010 PARIS Tél. : 01 42 49 49 73 - Fax : 01 42 49 47 43 E-mail : caroline.lascoux-combe@aphp.fr~Participating country : FRANCE~Primary objective : Comparing the kinetic of HIV-RNA decay in blood plasma and in seminal plasma in patients starting a triple combination regimen with dolutegravir + tenofovir DF (TDF) + emtricitabine (FTC) at the time of PHI.~Secondary objectives :~Comparison of HIV-1 RNA level in plasma (threshold 20 and 1 copies/ml) and in seminal plasma (threshold 60 copies/ml) at each visit D0, W2, W4, W8, W12, W24, W36, W48~To assess the frequency of intermittent shedding in seminal plasma once virological suppression has been achieved and until W48~Evolution of cellular HIV-1 DNA level in PBMC and in non-sperm cells between D0 and W48~Comparison of dolutegravir concentration in blood plasma and seminal plasma~Study of risk factors associated with viral persistence of HIV-RNA in the seminal plasma~Analysis by deep sequencing of the viral population (quasi-species) in both compartments (blood plasma and seminal plasma) before virological suppression has been achieved (i.e. at D0 and W12)~Inclusion criteria :~Patients diagnosed at the time of primary HIV infection (PHI) (i) a negative or indeterminate HIV ELISA associated with a positive antigenemia or plasma HIV RNA, (ii) a western blot profile compatible with ongoing seroconversion (incomplete western blot with absence of antibodies to pol proteins (p34, p68)) or (iii) an initially negative test for HIV antibodies followed within 3 months by a positive HIV serology~Treatment including dolutegravir (DTG 50mg) + tenofovir/emtricitabine (TDF/FTC 245 mg/200 mg) initiated by the referee physician within a maximum of 15 days after diagnosis of PHI~Genotypic sensitivity to TDF, FTC and DTG~Patient with medical care insurance~Exclusion criteria :~Chronic infection~Infection or co-infection with HIV-2~Study treatment : Dolutegravir and tenofovir/emtricitabine Number of subjets : 20 patients (exploratory study)